Health

American Cancer Society Issues Updated Guidance for Prostate Screening

The American Cancer Society (ACS) has released updated guidance recommending that average-risk men between the ages of 50 and 69 undergo prostate-specific antigen (PSA) blood testing every two years. This shift marks a departure from the organization’s 2010 recommendation, which advised that men should consult with their physicians to decide whether to pursue screening.

The new guidelines, published November 12, establish specific age and risk-based intervals. For men at higher risk—specifically Black men and those with a documented family history of the disease—the ACS recommends annual screening beginning at age 45 and continuing through age 69. For those aged 70 to 74, the organization suggests that patients and providers decide whether to continue screening, citing uncertainty regarding the balance of benefits and harms in that demographic. The ACS does not recommend routine screening for men aged 75 and older, though it notes that healthy individuals in that age group may choose to discuss screening options with their healthcare providers.

image

Dr. Robert Smith, senior vice president and director of the ACS center for early cancer detection, stated that the update aims to reduce mortality and morbidity through the identification of clinically significant tumors. The ACS cited a long-term European study of men aged 55 to 69, which concluded that prostate cancer deaths were 13% lower among those who received PSA testing compared to those who did not. Officials emphasized that this screening should be paired with follow-up protocols, such as MRIs and biomarker testing, to differentiate aggressive cancers from slower-growing, low-risk tumors that might not require immediate treatment.

Prostate cancer screening has long been a subject of debate due to concerns over overdiagnosis and the risks of false positives, which can lead to unnecessary biopsies and complications from treatments like radiation. Dr. William Dahut, chief scientific officer at the ACS, said that incorporating nuanced follow-up diagnostics, such as active surveillance for less aggressive cases, should help mitigate the frequency of unnecessary biopsies. Supporters of the new guidance, including Dr. Phillip Koo, chief medical officer of the Prostate Cancer Foundation, welcomed the more directive approach.

image

The American Cancer Society estimates that 333,830 U.S. men will be diagnosed with prostate cancer in 2026 and that 36,320 men will die from the disease. The updated recommendations follow years of fluctuating clinical consensus, including a 2018 recommendation from the U.S. Preventive Services Task Force that men aged 55 to 69 consider periodic testing, a shift from the task force’s 2012 guidance that discouraged such screening.

Evelyn Price

Evelyn Price covers health news, medical research, public health developments, and wellness topics. She aims to present evidence-based information in clear language, helping readers understand important studies, health policies, and advances in medicine.
Back to top button